AGX 509
Alternative Names: AGX-509Latest Information Update: 08 Oct 2024
At a glance
- Originator AgonOx
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 Aug 2024 Preclinical trials in Cancer in USA (Parenteral) (AgonOx pipeline; August 2024)